COV-Iran Barakat efficiency beyond expectations: Executive manager

The executive manager of the 'COV-Iran Barakat' vaccine's clinical trial said that the Iran-made vaccine's efficiency was beyond expectations.

According to Iran Press, Minoo Mohraz elaborated on the progress made on the 3rd phase of the clinical trial of the 'COV-Iran Barakat' vaccine at Eram Hotel on Sunday, saying: "With the mass production of the vaccine, we no longer need to import vaccines from abroad."

She said that the coronavirus outbreak had impacted the economic and educational aspects of the country, "so we must help everyone get vaccinated by October to reopen schools and universities."

In further remarks, Mohraz pointed out: "Everyone should be vaccinated," adding that given the shortage of vaccines globally, we must help people get vaccinated and get back to daily activities."

Mohraz noted: "COV-Iran Barakat's vaccine is effective and immune, and we hope that our vaccine would have the highest percentage of efficiency and immunity.”

Also, as the next keynote speaker, Hassan Jalili, the head of the vaccine production project in the Execution of Imam Khomeini's Order (EIKO), stated that the third phase of vaccine production would be launched in late spring.

Jalili said: "The production capacity of 'COV-Iran Barakat' is more than 10 million doses per month." 

Speaking on Sunday at the press conference of COV-Iran Barkat vaccine, he said that the third phase includes industrial production, adding: "In fact, this phase will be mass production, and we predict that this phase will be launched in late spring and the vaccine production capacity will be more than 10 million doses per month."

"We should not forget that the world has been ahead of us in vaccines developing because they have been affected by various viral diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)," Jalili noted.

He noted that Iran has now been able to indigenize and develop the vaccine.

ME